W. Ceelen and M. Flessner, Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence, Nature Reviews Clinical Oncology, vol.142, issue.2, pp.108-115, 2010.
DOI : 10.1038/nrclinonc.2009.217

O. Glehen, F. Mohamed, and F. Gilly, Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia, The Lancet Oncology, vol.5, issue.4, pp.219-228, 2004.
DOI : 10.1016/S1470-2045(04)01425-1

D. Elias, Is Intraperitoneal Chemotherapy After Cytoreductive Surgery Efficient? Knowing Whether It Is or Not Appears Secondary!, Annals of Surgical Oncology, vol.12, issue.1, pp.5-6, 2012.
DOI : 10.1245/s10434-011-1897-7

P. Sugarbaker, Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives?, The American Journal of Surgery, vol.201, issue.2, pp.157-159, 2011.
DOI : 10.1016/j.amjsurg.2010.04.010

C. Pomel, G. Ferron, G. Lorimier, A. Rey, and C. Lhomme, Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study, European Journal of Surgical Oncology (EJSO), vol.36, issue.6, pp.589-593, 2010.
DOI : 10.1016/j.ejso.2010.04.005

URL : https://hal.archives-ouvertes.fr/hal-00599226

P. Sugarbaker, Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach, Expert Opinion on Pharmacotherapy, vol.6, issue.12, pp.1965-1977, 2009.
DOI : 10.1200/JCO.2003.04.187

G. Glockzin, H. Schlitt, and P. Piso, Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, World Journal of Surgical Oncology, vol.7, issue.1, p.5, 2009.
DOI : 10.1186/1477-7819-7-5

J. Bell, B. Rylah, R. Chambers, H. Peet, and F. Mohamed, Perioperative Management of Patients Undergoing Cytoreductive Surgery Combined with Heated Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: A Multi-Institutional Experience, Annals of Surgical Oncology, vol.54, issue.13, 2012.
DOI : 10.1245/s10434-012-2496-y

M. Koppe, R. Bleichrodt, W. Oyen, and O. Boerman, Radioimmunotherapy and colorectal cancer, British Journal of Surgery, vol.256, issue.3, pp.264-276, 2005.
DOI : 10.1002/bjs.4936

F. Aarts, T. Hendriks, O. Boerman, M. Koppe, and W. Oyen, A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats, Annals of Surgical Oncology, vol.15, issue.11, pp.3274-3282, 2007.
DOI : 10.1245/s10434-007-9509-2

V. Boudousq, S. Ricaud, V. Garambois, C. Bascoul-mollevi, and S. Boutaleb, Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies, Journal of Nuclear Medicine, vol.51, issue.11, pp.1748-1755, 2010.
DOI : 10.2967/jnumed.110.080226

URL : https://hal.archives-ouvertes.fr/inserm-00531603

L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-mollevi, and V. Boudousq, Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2041, 2009.
DOI : 10.2967/jnumed.109.066993

URL : https://hal.archives-ouvertes.fr/inserm-00442929

R. Verheijen, L. Massuger, B. Benigno, A. Epenetos, and A. Lopes, Phase III Trial of Intraperitoneal Therapy With Yttrium-90???Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission, Journal of Clinical Oncology, vol.24, issue.4, pp.571-578, 2006.
DOI : 10.1200/JCO.2005.02.5973

A. Oei, R. Verheijen, M. Seiden, B. Benigno, and A. Lopes, Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival, International Journal of Cancer, vol.19, issue.12, pp.2710-2714, 2007.
DOI : 10.1002/ijc.22663

J. Pouget, I. Navarro-teulon, M. Bardies, N. Chouin, and G. Cartron, Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011.
DOI : 10.1038/nrclinonc.2011.160

R. Sharkey and D. Goldenberg, Cancer radioimmunotherapy, Immunotherapy, vol.3, issue.3, pp.349-370, 2011.
DOI : 10.2217/imt.10.114

URL : https://hal.archives-ouvertes.fr/hal-01258870

C. Boswell and M. Brechbiel, Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view, Nuclear Medicine and Biology, vol.34, issue.7, pp.757-778, 2007.
DOI : 10.1016/j.nucmedbio.2007.04.001

T. Nikula, M. Mcdevitt, R. Finn, C. Wu, and R. Kozak, Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry, J Nucl Med, vol.40, pp.166-176, 1999.

Z. Zhang, M. Zhang, K. Garmestani, V. Talanov, and P. Plascjak, Effective treatment of a murine model of adult T-cell leukemia using, 2006.

H. Song, K. Shahverdi, D. Huso, C. Esaias, and J. Fox, (alphaemitter )-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model, Cancer Res, vol.68, pp.213-3873, 2008.

M. Lingappa, H. Song, S. Thompson, F. Bruchertseifer, and A. Morgenstern, Immunoliposomal Delivery of 213Bi for ??-Emitter Targeting of Metastatic Breast Cancer, Cancer Research, vol.70, issue.17, pp.6815-6823, 2010.
DOI : 10.1158/0008-5472.CAN-09-4548

M. Mcdevitt, E. Barendswaard, D. Ma, L. Lai, and M. Curcio, An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer, Cancer Res, vol.60, pp.6095-6100, 2000.

D. Wild, M. Frischknecht, H. Zhang, A. Morgenstern, and F. Bruchertseifer, Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN), Cancer Research, vol.71, issue.3, pp.1009-1018, 2011.
DOI : 10.1158/0008-5472.CAN-10-1186

Y. Li, E. Song, A. Rizvi, S. Power, C. Beretov et al., Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted ?? Radioimmunoconjugates, Clinical Cancer Research, vol.15, issue.3, pp.865-875, 2009.
DOI : 10.1158/1078-0432.CCR-08-1203

E. Song, C. Qu, S. Rizvi, C. Raja, and J. Beretov, Bismuth-213 radioimmunotherapy with C595 anti???MUC1 monoclonal antibody in an ovarian cancer ascites model, Cancer Biology & Therapy, vol.7, issue.1, pp.76-80, 2008.
DOI : 10.4161/cbt.7.1.5132

J. Elgqvist, H. Andersson, T. Back, R. Hultborn, and H. Jensen, Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35, J Nucl Med, vol.46, pp.1907-1915, 2005.

A. Gustafsson, T. Back, J. Elgqvist, L. Jacobsson, and R. Hultborn, Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model, Nuclear Medicine and Biology, vol.39, issue.1, pp.15-22, 2012.
DOI : 10.1016/j.nucmedbio.2011.07.003

S. Palm, T. Back, I. Claesson, A. Danielsson, and J. Elgqvist, Therapeutic Efficacy of Astatine-211???Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.2, pp.572-579, 2007.
DOI : 10.1016/j.ijrobp.2007.06.023

J. Elgqvist, H. Andersson, T. Back, I. Claesson, and R. Hultborn, Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab???)2: therapeutic efficacy and myelotoxicity, Nuclear Medicine and Biology, vol.33, issue.8, pp.1065-1072, 2006.
DOI : 10.1016/j.nucmedbio.2006.07.009

D. Milenic, K. Garmestani, E. Brady, P. Albert, and D. Ma, Pb-Labeled Radioimmunoconjugate Targeting HER2, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.5, pp.557-568, 2005.
DOI : 10.1089/cbr.2005.20.557

D. Milenic, K. Garmestani, E. Brady, P. Albert, and A. Abdulla, Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease, Clinical Cancer Research, vol.13, issue.6, pp.1926-1935, 2007.
DOI : 10.1158/1078-0432.CCR-06-2300

Y. Almqvist, A. Steffen, H. Lundqvist, H. Jensen, and V. Tolmachev, At-Labeled Humanized Monoclonal Antibody A33, Cancer Biotherapy & Radiopharmaceuticals, vol.22, issue.4, pp.480-487, 2007.
DOI : 10.1089/cbr.2007.349A

B. Pfost, C. Seidl, M. Autenrieth, D. Saur, and F. Bruchertseifer, Intravesical ??-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice, Journal of Nuclear Medicine, vol.50, issue.10, pp.1700-1708, 2009.
DOI : 10.2967/jnumed.109.065961

E. Horak, F. Hartmann, K. Garmestani, C. Wu, and M. Brechbiel, Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1, J Nucl Med, vol.38, pp.1944-1950, 1997.

Z. Tan, P. Chen, N. Schneider, S. Glover, and L. Cui, Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice, Int J Oncol, vol.40, pp.1881-1888, 2012.

D. Milenic, K. Garmestani, E. Brady, K. Baidoo, and P. Albert, Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease, Clinical Cancer Research, vol.14, issue.16, pp.5108-5115, 2008.
DOI : 10.1158/1078-0432.CCR-08-0256

C. Hudis, Trastuzumab ??? Mechanism of Action and Use in Clinical Practice, New England Journal of Medicine, vol.357, issue.1, pp.39-51, 2007.
DOI : 10.1056/NEJMra043186

C. Ruegg, W. Anderson-berg, M. Brechbiel, S. Mirzadeh, and O. Gansow, Improved in vivo stability and tumor targeting of bismuth-labeled antibody, Cancer Res, vol.50, pp.4221-4226, 1990.

S. Hammarstrom, J. Shively, R. Paxton, B. Beatty, and A. Larsson, Antigenic sites in carcinoembryonic antigen, Cancer Res, vol.49, pp.4852-4858, 1989.

G. Kohler, S. Howe, and C. Milstein, Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines, European Journal of Immunology, vol.30, issue.4, pp.292-295, 1976.
DOI : 10.1002/eji.1830060411

B. Robert, J. Mach, J. Mani, M. Ychou, and S. Folli, Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha, Cancer Res, vol.56, pp.4758-4765, 1996.

J. Baselga, L. Norton, J. Albanell, Y. Kim, and J. Mendelsohn, Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res, vol.58, pp.2825-2831, 1998.

D. Milenic, K. Garmestani, E. Brady, P. Albert, and D. Ma, Pb-Labeled Radioimmunoconjugate Targeting HER2, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.5, pp.557-568, 2005.
DOI : 10.1089/cbr.2005.20.557

L. Chappell, E. Dadachova, D. Milenic, K. Garmestani, and C. Wu, Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb, Nuclear Medicine and Biology, vol.27, issue.1, pp.93-100, 2000.
DOI : 10.1016/S0969-8051(99)00086-4

K. Yong and M. Brechbiel, Towards translation of 212Pb as a clinical therapeutic; getting the lead in!, Dalton Transactions, vol.91, issue.8, pp.6068-6076, 2011.
DOI : 10.1039/c0dt01387k

E. Dadachova, L. Chappell, and M. Brechbiel, Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand???protein conjugates, Nuclear Medicine and Biology, vol.26, issue.8, pp.977-982, 1999.
DOI : 10.1016/S0969-8051(99)00054-2

Z. Tan, P. Chen, N. Schneider, S. Glover, and L. Cui, Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice, International journal of oncology, vol.40, pp.1881-1888, 2012.

K. Eckerman and E. Akira, MIRD: Radionuclide Data and Decay Schemes, 2008.

N. Chouin, K. Bernardeau, F. Davodeau, M. Cherel, and A. Faivre-chauvet, Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model, Radiation Research, vol.171, issue.6, pp.657-663, 2009.
DOI : 10.1667/RR1371.1

J. Dahle, N. Abbas, O. Bruland, and R. Larsen, Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates, Current Radiopharmaceuticalse, vol.4, issue.4, pp.321-328, 2011.
DOI : 10.2174/1874471011104040321

G. Sgouros, J. Roeske, M. Mcdevitt, S. Palm, and B. Allen, MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of ??-Particle Emitters for Targeted Radionuclide Therapy, Journal of Nuclear Medicine, vol.51, issue.2, pp.311-328, 2010.
DOI : 10.2967/jnumed.108.058651

J. Pouget, L. Santoro, R. L. Chouin, N. Bardies, and M. , Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons, Radiation Research, vol.170, issue.2, pp.192-200, 2008.
DOI : 10.1667/RR1359.1

URL : https://hal.archives-ouvertes.fr/inserm-00311037

G. Ruble, C. Wu, R. Squire, O. Ganswo, and M. Strand, The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia, International Journal of Radiation Oncology*Biology*Physics, vol.34, issue.3, 1996.
DOI : 10.1016/0360-3016(95)02119-1

J. Jurcic, S. Larson, G. Sgouros, M. Mcdevitt, and R. Finn, Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.1233-1239, 2002.
DOI : 10.14694/EdBook_AM.2014.34.e126

T. Rosenblat, M. Mcdevitt, D. Mulford, N. Pandit-taskar, and C. Divgi, Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5311, 2010.
DOI : 10.1158/1078-0432.CCR-10-0382

H. Andersson, E. Cederkrantz, T. Back, C. Divgi, and J. Elgqvist, Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009.
DOI : 10.2967/jnumed.109.062604

B. Allen, A. Singla, S. Rizvi, P. Graham, and F. Bruchertseifer, Analysis of patient survival in a Phase I trial of systemic targeted ??-therapy for metastatic melanoma, Immunotherapy, vol.3, issue.9, pp.1041-1050, 2011.
DOI : 10.2217/imt.11.97

M. Zalutsky, D. Reardon, G. Akabani, R. Coleman, and A. Friedman, Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008.
DOI : 10.2967/jnumed.107.046938